Overview

Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)

Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
A Phase 2 study of nivolumab plus ipilimumab in previously treated classical Kaposi Sarcoma (CKS)
Phase:
Phase 2
Details
Lead Sponsor:
Alona Zer
Collaborator:
Bristol-Myers Squibb
Treatments:
Antibodies, Monoclonal
Ipilimumab
Nivolumab